TAG: Increased dose resistance to usanut can improve the clinical response of patients with refrive Crohn's disease.

Treatments for patients with moderate to severe Crohn's disease (CD) are preferred for biologic therapy, and UST can block immune cells or IL-12/23 cytokine-mediated TNF alpha4 beta-7 integrator pathlines, thereby reducing inflammatory levels.
UST reduces inflammation of the mucous membranes of the colon and small intestine, eliminates lesions in fistula, and treats the extraintestinal manifestations of CD.
studies have shown that increasing the number of UST dose injections every 8 weeks to every 4 weeks (Q4 weeks) can improve clinical activity.
study is intended to validate this.
conducted a retrospective observational study of 143 adult CD patients who received UST over a 33-month 33-month age.
outcomes of the collection were clinical response (PGA) and remission (PGA) and mitigation (PGA s 0).
from the beginning of dose conversion, changes in clinical response in dose-increment patients were calculated and compared to a group of patients classified as "failed" at the standard dose at week 42 without dose increment.
results showed that the dose increase improved the PGA by 0.47±0.19 compared to taking the drug every 8 weeks (Q8 weeks), while patients who did not increase the dose worsened by 0.23±0.23 (p .lt;0.05).
dose increase reduces CRP 0.33±0.19 mg/ L levels and increases serum albumin concentrations by 0.23±0.06 g / dL (p .lt;0.05).
is surprising that the duration of the disease is inversely inversely related to the need for increased doses from previous CD surgery.
, the results of this study support the effectiveness of UST Q4 week dose increment therapy in some CD patients who failed to pass standard Q8 dose mitigation.
increased dose can improve clinical outcomes, prevent disease from worsening, and positively affect CRP and albumin levels.
.